Sorg Nadine, Poppe Carolin, Bunos Milica, Wingenfeld Eva, Hümmer Christiane, Krämer Ariane, Stock Belinda, Seifried Erhard, Bonig Halvard
German Red Cross Blood Service Baden-Württemberg-Hessen, Institute Frankfurt.
Institute for Transfusion Medicine and Immunohematology, Goethe University, Frankfurt, Germany.
Transfusion. 2015 Jun;55(6):1275-82. doi: 10.1111/trf.13001. Epub 2015 Feb 2.
Red blood cell (RBC) depletion is a standard technique for preparation of ABO-incompatible bone marrow transplants (BMTs). Density centrifugation or apheresis are used successfully at clinical scale. The advent of a bone marrow (BM) processing module for the Spectra Optia (Terumo BCT) provided the initiative to formally compare our standard technology, the COBE2991 (Ficoll, manual, "C") with the Spectra Optia BMP (apheresis, semiautomatic, "O"), the Sepax II NeatCell (Ficoll, automatic, "S"), the Miltenyi CliniMACS Prodigy density gradient separation system (Ficoll, automatic, "P"), and manual Ficoll ("M"). C and O handle larger product volumes than S, P, and M.
Technologies were assessed for RBC depletion, target cell (mononuclear cells [MNCs] for buffy coats [BCs], CD34+ cells for BM) recovery, and cost/labor. BC pools were simultaneously purged with C, O, S, and P; five to 18 BM samples were sequentially processed with C, O, S, and M.
Mean RBC removal with C was 97% (BCs) or 92% (BM). From both products, O removed 97%, and P, S, and M removed 99% of RBCs. MNC recovery from BC (98% C, 97% O, 65% P, 74% S) or CD34+ cell recovery from BM (92% C, 90% O, 67% S, 70% M) were best with C and O. Polymorphonuclear cells (PMNs) were depleted from BCs by P, S, and C, while O recovered 50% of PMNs. Time savings compared to C or M for all tested technologies are considerable.
All methods are in principle suitable and can be selected based on sample volume, available technology, and desired product specifications beyond RBC depletion and MNC and/or CD34+ cell recovery.
红细胞(RBC)去除是制备ABO血型不相合骨髓移植(BMT)的标准技术。密度离心法或单采术已在临床规模上成功应用。Spectra Optia(Terumo BCT)骨髓(BM)处理模块的出现促使我们正式比较我们的标准技术COBE2991(菲可分离液,手动,“C”)与Spectra Optia骨髓处理模块(单采术,半自动,“O”)、Sepax II NeatCell(菲可分离液,自动,“S”)、Miltenyi CliniMACS Prodigy密度梯度分离系统(菲可分离液,自动,“P”)以及手动菲可分离液法(“M”)。C和O处理的产品体积比S、P和M更大。
对这些技术进行了红细胞去除、目标细胞(用于 Buffy 层[BC]的单核细胞[MNC]、用于骨髓的CD34+细胞)回收率以及成本/人力方面的评估。用C、O、S和P同时清除BC池;用C、O、S和M依次处理5至18个骨髓样本。
C对BC的平均红细胞去除率为97%,对骨髓的为92%。O对两种产品的红细胞去除率均为97%,P、S和M的红细胞去除率为99%。C和O从BC中回收MNC的效率最高(C为98%,O为97%),从骨髓中回收CD34+细胞的效率也最高(C为92%,O为90%)。P、S和C能从BC中去除多形核细胞(PMN),而O能回收BC中50%的PMN。与C或M相比,所有测试技术在时间节省方面都很可观。
所有方法原则上都是适用的,可以根据样本量、可用技术以及除红细胞去除和MNC及/或CD34+细胞回收率之外的所需产品规格来选择。